ArticlePharmaceutics2022
Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Pooled it
- Adjunctive Anti-VEGF Therapy Influences on Early Visual Recovery Without Affecting Long-Term Outcomes or Intraocular Pressure After Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.Medical science monitor : international medical journal of experimental and clinical research · 2026Observational
- Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration.CPT: pharmacometrics & systems pharmacology · 2026Article
- Adoption patterns of anti-vascular endothelial growth factor therapies in retinal disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Comparative outcomes of aflibercept 8 mg and faricimab in neovascular AMD refractory to aflibercept 2 mg.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD.Eye (London, England) · 2026Article
- Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg.Journal of ophthalmology · 2026Article
- Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life.PloS one · 2026Article
- Reassessing high-dose ranibizumab in the era of durable anti-VEGF therapy.Frontiers in ophthalmology · 2026Article
- Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications.Journal of nanobiotechnology · 2025Review
- Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Novel Pharmacokinetic Bridging Strategy for Locally Acting Intravitreal Drug Products.The AAPS journal · 2025Article
- Macular Edema in Diabetic Neovascular Glaucoma and Its Association with Systemic Diseases.Korean journal of ophthalmology : KJO · 2025Article
- Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis.Eye (London, England) · 2025Observational
- Beyond the injection: delivery systems reshaping retinal disease management.Expert opinion on pharmacotherapy · 2025Review
- From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD.Eye (London, England) · 2025Article
- Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.Eye (London, England) · 2025Review
- Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report.BMC ophthalmology · 2025Article
- Article
- Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA drug and disease assessment model was used to evaluate the impact of different treatment regimens on intravitreal ranibizumab, bevacizumab, aflibercept, and brolucizumab concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF.
methodsA time-dependent mathematical model using Wolfram Mathematica software was used. The pharmacokinetic and pharmacodynamic data for anti-VEGFs were obtained from published reports. The model simulated drug concentration after single and multiple doses of ranibizumab, bevacizumab, aflibercept, and brolucizumab, and it extrapolated time-dependent intraocular free VEGF proportion values. Various fixed treatment regimens (q4, q8, q10, q12) were simulated and evaluated as candidates for clinical utilization.
resultsOur mathematical model shows good correlation between intraocular VEGF proportion values and clinical data. Simulations suggest that each anti-VEGF agent would allow for distinct treatment intervals to keep the proportion of free VEGF under threshold levels. Regimens scheduling q8 ranibizumab, q8 bevacizumab, q12 aflibercept, and q10 brolucizumab administration permit to maintain the proportion of unbound VEGF below 0.001%.
conclusionsFixed q8 ranibizumab, q8 bevacizumab, q12 aflibercept, or q10 brolucizumab regimens may produce adequate intraocular VEGF inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.